Crysvita Restores Phosphate Balance, Improves Bone Health in Adults With XLH, Phase 3 Trial Shows
Treatment with Crysvita (burosumab) restores phosphate balance and improves bone mineralization in adults with X‐linked hypophosphatemia (XLH), a Phase 3 trial shows. The findings were reported in a study, “Burosumab Improved Histomorphometric Measures of Osteomalacia in Adults with X‐Linked Hypophosphatemia: A Phase 3, Single‐Arm,…